Adult myeloid leukaemias: Current and future treatments
Acute myeloid leukaemia is treated with chemotherapy and, if appropriate, stem cell transplantation. For those with chronic myeloid leukaemia, therapy has been transformed by tyrosine kinase inhibitors
The management of chronic myeloid leukaemia has been revolutionised by the discovery of imatinib and other tyrosine kinase inhibitors.
However, there is still significant progress to be made in the pharmacological treatment of acute myeloid leukaemia (AML) and the myelodysplastic syndromes, since the prognosis of particular subgroups (eg, elderly patients with AML and patients with MDS who are deemed to be at higher risk) remains poor.
With research ongoing into several novel, targeted therapies, the hope is that the incremental improvements in patient outcomes, which have been demonstrated over the past few decades, will continue to be seen in the future. Concerns remain about whether the significant acquisition costs associated with these novel therapies will prevent their adoption into routine clinical practice.
Nick Duncan is principal pharmacist for haematology/oncology at University Hospitals Birmingham NHS Foundation Trust.
Citation: Clinical Pharmacist URI: 11004809
Recommended from Pharmaceutical Press